In our study, we observed an increase in the counts of T cells, mainly CD8+ T cells, in disease-controlled patients, thus suggesting that some of our patients with hyperbilirubinemia can still respond to PD-1 inhibitors. Here, CD8A is linked to Hyperbilirubinemia.